Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TILT: Polyclonal Tregs + IL-2 for Type 1 Diabetes
NCT02772679Phase 1Completed
- Start
- Aug 2016
- Primary completion
- Aug 2021
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of Polyclonal Regulatory T Cells in type 1 diabetes mellitus (T1D) (2 arms). Primary endpoints: Adverse events at 3 years and Survival of Tregs at 3 years. Started Aug 2016; status: completed.
02
Drugs
Polyclonal Regulatory T Cells
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT02772679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02772679.